Clinical trials: Epithelial-Mesenchymal Transition
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Solid Tumors, Lymphoma
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Background: The new drug LMP744 (NSC 706744) damages deoxyribonucleic acid (DNA). This causes cell death. Researchers want to see if it can treat certain kinds of cancer.
- Trial name
- NCT03030417
- Testing
- LMP744, Ondansetron, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Advanced Solid Tumor
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically…
- Trial name
- NCT07181681
- Testing
- BG-C0902
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 63 people
- Sponsor
- BeOne Medicines
Solid Tumor
QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
This is a phase 2 study of AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations resulting in MET exon 14 skipping.
- Trial name
- NCT03147976
- Testing
- AMG 337
- Where
- United States
- Sponsor
- NantPharma, LLC
Periodontitis, Periodontal Diseases
Epithelial Mesenchymal Transition and Periodontitis
Periodontitis is a chronic inflammatory disease results is destruction of the attachment apparatus of the teeth and ultimately tooth loss.
- Conditions
- Periodontitis, Periodontal Diseases, Epithelial-Mesenchymal Transition, Transcription Factors
- Trial name
- NCT05403164
- Testing
- Modified Widman flap, Gingivectomy
- Where
- Iraq
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Baghdad
Multiple Myeloma
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
Based on our previous observations, here the investigator plans to further investigate eNAMPT in MM biology and to establish its role in disease progression where EMT acquisition represents an hallmark of cancers.
- Trial name
- NCT04137523
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- University of Turin, Italy
Advanced Solid Tumors
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
- Trial name
- NCT05541822
- Testing
- Vabametkib, Lazertinib
- Where
- 24 sites in United States, South Korea and 1 more
- Volunteers
- 178 people
- Sponsor
- Abion Inc
Prostate Cancer
Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology
This is a minimal risk correlative clinical blood-drawing protocol. The objective of this lead in pilot component is to determine whether Circulating Tumor Cells (CTC's) can be captured using the novel mesenchymal-marker based…
- Trial name
- NCT02022904
- Testing
- Near infrared (NIR) emissive nanotechnology
- Sponsor
- Duke University
Prostate Cancer
Influence of EMT on CTCs and Disease Progression in Prostate Cancer
The presence of circulating tumor cells (CTCs) in the blood of prostate cancer patients has been shown to be an important indicator of metastatic disease and poor prognosis.
- Trial name
- NCT04021394
- Testing
- CellSearch CTC platform, Parsortix CTC platform
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Renal Cell Carcinoma
Moesin Expression in Clear Cell Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes.
- Trial name
- NCT06055660
- Testing
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- Volunteers
- 50 people
- Sponsor
- Sohag University
Advanced NSCLC
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called…
- Trial name
- NCT04982224
- Testing
- REGN5093-M114, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Carcinoma
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT05110196
- Testing
- Capmatinib 150 mg, Capmatinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
End-Stage Kidney Disease, Peritoneal Dialysis
Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time.
- Trial name
- NCT01111422
- Testing
- N-acetylcysteine
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Ewha Womans University
Neoplasms, Neoplasm Metastasis
A Study of LY3164530 in Participants With Cancer
The main purpose of this study is to evaluate the safety of a study drug known as LY3164530 in participants with cancer that is advanced and/or has spread to another part(s) of the body.
- Trial name
- NCT02221882
- Testing
- LY3164530
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323917
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Non-Small Cell Lung Cancer, Solid Tumor
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for…
- Trial name
- NCT05940116
- Testing
- HS-20117
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Hansoh BioMedical R&D Company
Periodontal Disease, AVDC Stage 3and 4, Epithelial Mesenchymal Transition
The Potential Association of Long Non-coding RNA (NEAT1 and MALAT1) in the Process of Epithelial-mesenchymal Transition in Periodontitis
Periodontitis is a polymicrobial, inflammatory condition affecting tooth-supporting tissues. It is characterized by a progressive loss of epithelial attachment and resorption of alveolar bone, which can lead to tooth loss.
- Conditions
- Periodontal Disease, AVDC Stage 3and 4, Epithelial Mesenchymal Transition, Long Noncoding RNA
- Trial name
- NCT05995067
- Testing
- periodontitis challenge
- Where
- Iraq
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ali A Abdulkareem
Renal Interstitial Fibrosis
Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Recently, early biomarkers of renal interstitial fibrosis have been identified, amongst them de novo expression of vimentin by tubular epithelial cells, which is an intermediate filament, and the translocation of beta-catenin…
- Trial name
- CERTITEM (NCT01079143)
- Testing
- Certican®, Neoral, Myfortic
- Where
- 23 sites in France
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small Cell Lung, Adenocarcinoma
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
Background: PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be more active in cancer cells than normal cells, in particular in non-small cell lung cancer.
- Conditions
- Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell, Carcinoma, Large Cell
- Trial name
- NCT01441128
- Testing
- PF-02341066/PF-00299804
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal…
- Trial name
- RILOMET-1 (NCT01697072)
- Testing
- Rilotumumab, Epirubicin, Cisplatin
- Where
- 189 sites in United States, Australia and 25 more
- Volunteers
- 609 people
- Sponsor
- Amgen